Schwartz, S. S., & Katz, A. (2016). Sodium–glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: Focus on dapagliflozin–metformin. Diabetes Metab Syndr Obes.
Citação norma ChicagoSchwartz, Stanley S., and Arie Katz. "Sodium–glucose Cotransporter-2 Inhibitor Combination Therapy to Optimize Glycemic Control and Tolerability in Patients With Type 2 Diabetes: Focus On Dapagliflozin–metformin." Diabetes Metab Syndr Obes 2016.
Citação norma MLASchwartz, Stanley S., and Arie Katz. "Sodium–glucose Cotransporter-2 Inhibitor Combination Therapy to Optimize Glycemic Control and Tolerability in Patients With Type 2 Diabetes: Focus On Dapagliflozin–metformin." Diabetes Metab Syndr Obes 2016.